Drugs / Listaftoclax
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06401603 | Aug 2024 → Jan 2027 expected | Philadelphia-positive myelogenous leukemia, chronic myeloid leukemia | M.D. Anderson Cancer Center | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Listaftoclax | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06401603 ↗ |
| Route | Oral | “Given by PO” NCT06401603 ↗ |